China closing in but US leads in biotech quality and commercial reach, survey finds (opens original article in a new tab)

China leads in clinical development and supply chain but lags in biomedical science quality and commercial reach, while the US maintains leadership in drug production and commercialization, according to a survey.

• China conducts more clinical drug trials than the US but lags in biomedical science quality and commercial reach.
• US leads in moving experimental products to large-scale production, capital, and commercialization, while China is tied with the US in scientific discovery.
• China's share of global early drug development programs rose to 32% by 2024, while the US share dropped to 37% from 48% in 2015.